Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
OKYO Pharma Limited Sponsored ADR (OKYO)
NASDAQ:OKYO
RESEARCH TOOLSreports
Holding OKYO?
Track your performance easily
OKYO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.81 - $2.12
Previous Close$1.06
Volume54.30K
Average Volume (3M)56.18K
Market Cap
$35.92M
Enterprise Value$35.11M
Total Cash (Recent Filing)£633.63K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Aug 05, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding33,840,000
10 Day Avg. Volume17,272
30 Day Avg. Volume56,181
Standard Deviation0.19
R-Squared0.00240
Alpha-0.00505
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.00Price Target Upside573.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
OKYO Pharma Limited Sponsored ADR News
PremiumCompany Announcements
OKYO Pharma to Highlight Innovations at BTIG Conference
PremiumCompany Announcements
OKYO Pharma Advances in Ocular Treatment Trials
PremiumCompany Announcements
OKYO Pharma Begins Key Trial for Eye Pain Therapy
PremiumCompany Announcements
OKYO Pharma Begins Key Phase 2 Trial for Eye Pain Drug
PremiumCompany Announcements
OKYO Pharma Chairman Boosts Stake, Advances Trials
Bulls Say, Bears Say
Bulls Say
Clinical EvaluationOK-101 has demonstrated favorable safety and tolerability in a Phase 2 trial in dry eye disease, with statistically significant improvements in symptoms such as stinging/burning and ocular pain.
Market PotentialNCP represents an urgent unmet medical need and an effective NCP treatment may have significant market prospects.
Strategic PartnershipsManagement noted that the company continues to explore strategic partnerships and collaborations to accelerate the development and commercialization.
Bears Say
Clinical TrialsThere is a risk of failure in the clinical trials of OK-101, which could impact investor confidence and stock valuation.
Market CompetitionOK-101 may struggle to achieve commercial success due to intense market competition and challenges in market penetration.
Regulatory ApprovalThe inability to secure regulatory approval for OK-101 in the U.S. poses a significant threat to the company's growth prospects.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.04% Mutual Funds
― Other Institutional Investors
99.96% Public Companies and
Individual Investors
OKYO FAQ
What was OKYO Pharma Limited Sponsored ADR’s price range in the past 12 months?
OKYO Pharma Limited Sponsored ADR lowest stock price was $0.81 and its highest was $2.12 in the past 12 months.
What is OKYO Pharma Limited Sponsored ADR’s market cap?
Currently, no data Available
When is OKYO Pharma Limited Sponsored ADR’s upcoming earnings report date?
OKYO Pharma Limited Sponsored ADR’s upcoming earnings report date is Aug 05, 2025 which is in 226 days.
How were OKYO Pharma Limited Sponsored ADR’s earnings last quarter?
OKYO Pharma Limited Sponsored ADR released its earnings results on Nov 29, 2024. The company reported -$0.09 earnings per share for the quarter, the consensus estimate of -$0.09 by $0.
Is OKYO Pharma Limited Sponsored ADR overvalued?
According to Wall Street analysts OKYO Pharma Limited Sponsored ADR’s price is currently Undervalued.
Does OKYO Pharma Limited Sponsored ADR pay dividends?
OKYO Pharma Limited Sponsored ADR does not currently pay dividends.
What is OKYO Pharma Limited Sponsored ADR’s EPS estimate?
OKYO Pharma Limited Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OKYO Pharma Limited Sponsored ADR have?
OKYO Pharma Limited Sponsored ADR has 33,886,314 shares outstanding.
What happened to OKYO Pharma Limited Sponsored ADR’s price movement after its last earnings report?
OKYO Pharma Limited Sponsored ADR reported an EPS of -$0.09 in its last earnings report, expectations of -$0.09. Following the earnings report the stock price went down -1.923%.
Which hedge fund is a major shareholder of OKYO Pharma Limited Sponsored ADR?
Currently, no hedge funds are holding shares in OKYO
---
OKYO Pharma Limited Sponsored ADR Stock Smart Score
Company Description
OKYO Pharma Limited Sponsored ADR
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
---
OKYO Stock 12 Month Forecast
Average Price Target
$7.00
▲(573.01% Upside)
Technical Analysis
Best Analysts Covering OKYO
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-24.80%
reiterated a buy rating 2 months ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -24.80% per trade.
---